Trends in incidence, mortality and survival of testicular cancer patients in Belarus.
incidence
mortality
proportional hazards models
survival analysis
testicular germ cell tumor
testicular neoplasms
Journal
Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
11
2019
revised:
29
11
2019
accepted:
30
11
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
The objective of this study was to assess recent trends in incidence, mortality and relative survival (RS) in testicular cancer (TC) patients in Belarus and to provide international comparisons of our figures. We surveyed the Belarusian Cancer Registry for all male cases diagnosed with International Classification of Diseases for Oncology, third edition (ICD-O-3) topography code C62 between 1990 and 2015. Trends for incidence and mortality rates per 100,000 of the world standard population and annual percentage changes (APCs) were calculated. We also estimated the 1- and 5-year RS rates for the 1990-1998, 1999-2007 and 2008-2015 periods according to the Ederer II method. The RS estimates for the 2008-2015 period were age-standardized and compared with the published EUROCARE-5 data and SEER-18 database analysis. A total of 2,500 and 2,439 cases were included into incidence and survival analyses, respectively. We found a significant increase in the TC age-standardized incidence rate (APC 2.6%) and a decline in the age-standardized mortality (APC -3.0%) over the study period. RS significantly increased in all patients` strata; a relative increase was more pronounced in advanced stages of seminoma and younger age groups. Nevertheless, the most recent figures of age-standardized RS including stage-specific estimates were generally worse than the European and SEER data. We have found a significant increase in TC incidence in Belarus in recent years. Mortality has significantly declined with a corresponding increase in RS which, however, did not reach European or North American figures. Continued effort is required to improve the quality of management of TC patients in our country.
Identifiants
pubmed: 32015904
doi: 10.5173/ceju.2019.0073
pii: 0073
pmc: PMC6979549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
357-368Informations de copyright
Copyright by Polish Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest
Références
Eur J Cancer. 2014 Mar;50(4):831-9
pubmed: 24369860
Cancer Epidemiol. 2019 Feb;58:175-177
pubmed: 30616087
N Engl J Med. 2014 Nov 20;371(21):2005-16
pubmed: 25409373
Urology. 2015 Jun;85(6):1394-8
pubmed: 26099885
BJU Int. 2017 Dec;120(6):799-807
pubmed: 28480994
Urol Oncol. 2012 Jul-Aug;30(4):487-93
pubmed: 20870430
Ann Oncol. 2013 Feb;24(2):508-13
pubmed: 23110807
Cancer Epidemiol. 2012 Feb;36(1):11-5
pubmed: 22014475
Acta Oncol. 2012 Sep;51(7):956-8
pubmed: 22548368
Cancer. 2011 Sep 15;117(18):4277-85
pubmed: 21387261
Eur J Cancer. 2004 Oct;40(15):2307-16
pubmed: 15454257
BJU Int. 2019 Mar;123(3):385-387
pubmed: 30536825
Biostatistics. 2009 Jan;10(1):136-46
pubmed: 18599516
Eur J Cancer. 2015 Oct;51(15):2206-2216
pubmed: 26421823
Lancet. 2001 Jun 9;357(9271):1853-4
pubmed: 11410198
Eur Urol. 2014 Jun;65(6):1095-106
pubmed: 24268506
J Clin Oncol. 2011 Mar 10;29(8):963-70
pubmed: 21300926
Cancer Epidemiol. 2012 Apr;36(2):217-21
pubmed: 21890445
Urology. 2016 Jan;87:140-5
pubmed: 26477833
Int J Cancer. 2006 Jun 15;118(12):3099-111
pubmed: 16395710
Eur Urol Focus. 2017 Dec;3(6):621-628
pubmed: 28753801
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615